Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial
B Hoen, B Dumon, M Harzic, A Venet… - The Journal of …, 1999 - academic.oup.com
B Hoen, B Dumon, M Harzic, A Venet, B Dubeaux, C Lascoux, Y Bourezane, JM Ragnaud…
The Journal of infectious diseases, 1999•academic.oup.comHighly active antiretroviral treatment (HAART) was given early to 64 patients with
symptomatic primary human immunodeficiency virus (HIV)-1 infection. At the time of
analysis, patients had been followed up for 9–21 months. No patient had died or developed
an AIDS-defining event. Survival analysis showed that by month 21 the proportion of
patients with plasma HIV-1 RNA< 50 copies/mL was 72%(95% confidence interval, 58%–
95%) in intention-to-treat analysis. After 18 months of treatment, 50% of the patients with …
symptomatic primary human immunodeficiency virus (HIV)-1 infection. At the time of
analysis, patients had been followed up for 9–21 months. No patient had died or developed
an AIDS-defining event. Survival analysis showed that by month 21 the proportion of
patients with plasma HIV-1 RNA< 50 copies/mL was 72%(95% confidence interval, 58%–
95%) in intention-to-treat analysis. After 18 months of treatment, 50% of the patients with …
Abstract
Highly active antiretroviral treatment (HAART) was given early to 64 patients with symptomatic primary human immunodeficiency virus (HIV)-1 infection. At the time of analysis, patients had been followed up for 9–21 months. No patient had died or developed an AIDS-defining event. Survival analysis showed that by month 21 the proportion of patients with plasma HIV-1 RNA <50 copies/mL was 72% (95% confidence interval, 58%–95%) in intention-to-treat analysis. After 18 months of treatment, 50% of the patients with undetectable plasma HIV-1 RNA also had undetectable HIV-1 RNA in peripheral blood mononuclear cells (PBMC). Only 1 of 3 patients had undetectable HIV-1 RNA in lymphoid tissue, while all patients had quantifiable HIV-1 DNA both in PBMC and lymphoid tissue. The median CD4 lymphocyte increase from baseline was 230 cells/μL. These preliminary results support the use of HAART in patients with primary HIV-1 infection.
Oxford University Press